These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7725383)

  • 1. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
    Dias VC; Lucien J; LeGatt DF; Yatscoff RW
    Ther Drug Monit; 1995 Feb; 17(1):84-8. PubMed ID: 7725383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
    Schmidt A; Schwind B; Gillich M; Brune K; Hinz B
    Biomed Chromatogr; 2003 Jun; 17(4):276-81. PubMed ID: 12833393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood distribution and single-dose pharmacokinetics of leflunomide.
    Lucien J; Dias VC; LeGatt DF; Yatscoff RW
    Ther Drug Monit; 1995 Oct; 17(5):454-9. PubMed ID: 8585107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
    van Roon EN; Jansen TL; van de Laar MA; Janssen M; Yska JP; Keuper R; Houtman PM; Brouwers JR
    Ann Rheum Dis; 2005 Apr; 64(4):569-74. PubMed ID: 15345501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography.
    Chan V; Charles BG; Tett SE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(2):331-5. PubMed ID: 15063344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy.
    van Roon EN; Yska JP; Raemaekers J; Jansen TL; van Wanrooy M; Brouwers JR
    J Pharm Biomed Anal; 2004 Sep; 36(1):17-22. PubMed ID: 15351043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats.
    Mehl ML; Tell L; Kyles AE; Chen YJ; Craigmill A; Gregory CR
    J Vet Pharmacol Ther; 2012 Apr; 35(2):139-46. PubMed ID: 21615755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
    Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
    Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
    Hossain MM; Margolis DM
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
    Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
    Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
    Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
    Chan V; Charles BG; Tett SE
    Br J Clin Pharmacol; 2005 Sep; 60(3):257-64. PubMed ID: 16120064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
    Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
    J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.
    Krisl JC; Taber DJ; Pilch N; Chavin K; Bratton C; Thomas B; McGillicuddy J; Baliga P
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1003-9. PubMed ID: 22461534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726.
    Seah QM; New LS; Chan EC; Boelsterli UA
    Drug Metab Lett; 2008 Aug; 2(3):153-7. PubMed ID: 19356086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
    Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
    J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
    Williams CR; Sykes JE; Mehl M; MacLeod JS; Lindsay LL; Poland AM; Chen YJ; Kyles AE; Waldman WJ; Gregory CR
    Am J Vet Res; 2007 Sep; 68(9):1010-5. PubMed ID: 17764417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
    Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
    Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide and malononitrilamides.
    Silva Júnior HT; Morris RE
    Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes.
    Shi Q; Yang X; Greenhaw J; Salminen WF
    Toxicol Sci; 2011 Aug; 122(2):579-86. PubMed ID: 21546349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.